Lhasa Limited shared knowledge shared progress
Publications
  • Publisher:
    Elsevier
  • Publication Date:
    Mar 2013
  • Reference:
    Regulatory Toxicology and Pharmacology, 2013, 65(2), pp201-213
  • DOI:
    10.1016/j.yrtph.2012.11.008
  • PMID:
  • Publication Type:
    Paper
  • Related Products:
  • Scientific Area:
  • Endpoint:
    • Carcinogenicity
    • Mutagenicity
  • Industry Type:
  • Related event:

Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis

Dobo KL; Ellis P; Kenyon MO;

The synthesis of pharmaceutical products often involves the use of reactive starting materials and intermediates. Low levels may be present in the final product as impurities and of particular concern are impurities that have mutagenic and carcinogenic potential. Regulatory guidance documents provide a general framework to minimise human exposure to these impurities; however, compound-specific recommendations are limited. Our practical experience with 11 pharmaceutical impurities is presented. 

Visit site

© 2018 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.

IP: 54.84.236.168 | Group: ###groupid###